Engel Law PLLC is investigating whether fair value to Adaptimmune shareholders will result from the proposed merger of Adaptimmune Therapeutics plc (Nasdaq: ADAP) with TCR² Therapeutics Inc., in which Adaptimmune will acquire all outstanding shares of TCR² common stock for 0.47233 shares of Adaptimmune for each TCR² share.
The Firm’s investigation concerns:
(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.